MedTrace Logo

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

NCT04130997 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1100

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).

Conditions

  • Relapsing Multiple Sclerosis (RMS)

Interventions

BIOLOGICAL

Ublituximab

Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.

Sponsors & Collaborators

  • TG Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2032-05-31
Completion
2032-05-31
FDA Drug
Yes

Countries

  • United States
  • Belarus
  • Croatia
  • Georgia
  • Poland
  • Russia
  • Serbia
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04130997 on ClinicalTrials.gov